- |||||||||| Generex Oral-lyn (insulin buccal spray) / Generex, Dong Sung Pharma, Shreya Life Sci, Afrezza (recombinant human insulin inhalation) / MannKind
Journal: Celebrating A Century Of Insulin Discovery: A Critical Appraisal Of The Emerging Alternative Insulin Delivery Systems. (Pubmed Central) - Mar 27, 2023
These efforts have not been without victory, as we have seen the emergence of pulmonary (Exubera and Afrezza) and buccal insulin delivery systems licenced for therapeutic use...However, at present, there are no clinical studies that have reported the efficacy of transdermal insulin administration With technological advancement, there is a potential to develop yet another insulin delivery system which would likely enter the markets. Although these novel delivery systems are welcome, however, emerging competing products should be welcome and appreciated.
- |||||||||| Generex Oral-lyn (insulin buccal spray) / Generex, Dong Sung Pharma, Shreya Life Sci
Journal: Deformable Nanovesicle-Loaded Gel for Buccal Insulin Delivery. (Pubmed Central) - Nov 15, 2022
Moreover, neither IPC-DNVs nor IPC-DNV-TSG induced significant mucosal irritation in rabbit tongue tissue sections. The study findings demonstrate a promising method for possible use as oral mucosal delivery of peptide drugs.
- |||||||||| Generex Oral-lyn (insulin buccal spray) / Generex, Dong Sung Pharma, Shreya Life Sci
Preclinical, Journal: Facilitated Buccal Insulin Delivery via Hydrophobic Ion-Pairing Approach: In vitro and ex vivo Evaluation. (Pubmed Central) - Jul 28, 2021
The increase in fluorescence intensity was observed in the order of C1 > C2 > insulin solution. In this study, we highlighted the efficacy of potential nanocarriers in addressing the daunting issues associated with the invasive administration of insulin and indicated a promising strategy for the buccal administration and delivery of this life-saving peptide hormone.
- |||||||||| Generex Oral-lyn (insulin buccal spray) / Generex, Dong Sung Pharma, Shreya Life Sci
Journal: Cell-Penetrating Peptide Enhanced Insulin Buccal Absorption. (Pubmed Central) - Feb 24, 2021
The objective of this study was to propose a novel protein delivery strategy to overcome the poor efficacy and irritation of buccal insulin delivery...INS-PEG-LMWP's relative pharmacological bioavailability was high and its relative bioavailability was up to 26.86%, demonstrating no visible mucosal irritation. Cell-penetrating peptides are likely to become a reliable and safe tool for overcoming insulin's low permeability through the epithelial multilayers, the major barrier to buccal delivery.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Speaker (Auditorium) - Oct 2, 2019 - Abstract #IDF2019IDF_497;
Newer inhaled insulin Afrezza based on a technosphere platform contains recombinant human insulin administered via a small thumb-sized device introduced in 2014 with modification in the size of the device...Other different ways of administration of insulin which can bypass hepatic first-pass metabolism are in a different phase of trial like buccal insulin, nasal insulin, ocular insulin; rectal insulin (bypasses the more proximal areas that are actively involved indigestion)...It then deploys milliposts fabricated from active pharmaceutical ingredients directly through the gastric mucosa while avoiding perforation. The preclinical study result has shown that SOMA has released the same plasma level of insulin compare to subcutaneous Learning Objectives History and development of insulinCurrent insulin therapy and delivery devices Future of insulin and its administration techniques
- |||||||||| Generex Oral-lyn (insulin buccal spray) / Generex, Dong Sung Pharma, Shreya Life Sciences, Afrezza (recombinant human insulin inhalation) / MannKind
Clinical, Review, Journal: A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade. (Pubmed Central) - Aug 3, 2019
To increase patient compliance, products are slowly reaching the market that are more patient friendly, such as the insulin patch-pump systems, including Omnipod and V-Go, but also the inhaled-insulin Afrezza and the buccal insulin Oral-lyn™. In this review, we outline the history of insulin, the various options that are currently available in practice for insulin delivery, and the non-invasive delivery systems that have entered the different stages of clinical trials over the past decade.
|
